Open-label, Non-randomized, Non-comparative, Phase II Study of Safety and Immunogenicity of Combination of AZD1222 and rAd26-S for COVID-19 Prevention
Open-label, Non-randomized, Non-comparative, Phase II Study in Adult Subjects to Assess Safety and Immunogenicity of Combination of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, and rAd26-S, a Recombinant Adenovirus Type 26 Component of Gam-COVID-Vac Vaccine, for COVID-19 Prevention
Sponsor: AstraZeneca
Listed as NCT04686773, this PHASE2 trial focuses on COVID-19 and remains completed. Sponsored by AstraZeneca, it has been updated 7 times since 2021, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jul 2022 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Feb 2022 — Jul 2022 [monthly]
Active Not Recruiting PHASE2
Status: Not Yet Recruiting → Active Not Recruiting
-
Oct 2021 — Feb 2022 [monthly]
Not Yet Recruiting PHASE2
▶ Show 2 earlier versions
-
Feb 2021 — Oct 2021 [monthly]
Not Yet Recruiting PHASE2
-
Jan 2021 — Feb 2021 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
- R-Pharm
- Russian Direct Investment Fund
- The Gamaleya National Center of Epidemiology & Microbiology
For direct contact, visit the study record on ClinicalTrials.gov .